TICKERNERD
Menu
AVIRAVIRHealthcare · Biotechnology

AVIR Stock Forecast: Atea Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$5.32
+0.19% on the day

The 3 Wall Street analysts covering Atea Pharmaceuticals, Inc. hold a median 12-month price target of $10 — +88.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$426.7M
Ticker Nerd rank
67 / 100
Median analyst target
$10
Analysts covering
3
Revenue$0.0
Operating income−$35.1M
Net income−$32.9M
Free cash flow−$37.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.7%
1M
+3.9%
YTD
+49.0%
1Y
+69.4%
From 52W high
−13.5%
From 52W low
+88.7%
$2.82
$6.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVIR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Atea Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
95
Issuance
86
Momentum
79
Accruals
70
Value
61
Size
55
Revisions
44
Quality
44
Growth
18

Volatility (95): The share price has been relatively steady.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVIR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVIR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26AVIRHigh $11Median $10Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $7Median $10High $11

The green dot is the last close — the median target sits +88.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Morgan StanleyMaintainsEqual-Weight$6.00 → $7.00
9 Mar 2026Evercore ISI GroupMaintainsOutperform—
9 Mar 2026Evercore ISI GroupMaintainsOutperform$6.00 → $10
11 Apr 2025Morgan StanleyMaintainsEqual-Weight—
13 Aug 2024Morgan StanleyUpgradeEqual-Weight—
10 Aug 2023JP MorganDowngradeUnderweight—
16 Mar 2023JP MorganMaintainsNeutral—
27 Jan 2023SVB LeerinkMaintainsMarket Perform—
24 Jan 2023Morgan StanleyMaintainsUnderweight—
15 Aug 2022Morgan StanleyMaintainsUnderweight—
2 Mar 2022JP MorganMaintainsNeutral—
1 Mar 2022SVB LeerinkMaintainsMarket Perform—
16 Feb 2022SVB LeerinkMaintainsMarket Perform—
6 Jan 2022Morgan StanleyDowngradeUnderweight—
18 Nov 2021SVB LeerinkDowngradeMarket Perform—
20 Oct 2021JP MorganDowngradeNeutral—
20 Oct 2021SVB LeerinkMaintainsOutperform—
5 Oct 2021Morgan StanleyDowngradeEqual-Weight—
9 Sept 2021SVB LeerinkInitiatesOutperform—
18 Aug 2021Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVIR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AVIR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Atea Pharmaceuticals, Inc. returned +69.4% against +17.0% for the S&P 500, dividends included.

AVIR vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26AVIRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVIR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Atea Pharmaceuticals, Inc. (AVIR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.7×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
2.1×

Cheaper than 44% of US stocks

EV / EBITDA
−1.1×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−58.1%

Higher than 20% of US stocks

Return on assets
−36.7%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Atea Pharmaceuticals, Inc. (AVIR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Atea Pharmaceuticals, Inc. has a market value of $426.7M and an enterprise value of $206.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$165.3M.

  • Diluted earnings per share, trailing twelve months: $−2.08.

  • Free cash flow in the twelve months to 30 June 2026: −$152.1M.

  • Atea Pharmaceuticals, Inc. spent $11.4M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 80.2M.

  • Trailing P/E: −2.7×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Atea Pharmaceuticals, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

AVIR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVIRAtea Pharmaceuticals, Inc.$426.7M
67
CCCCC4 Therapeutics, Inc.$431.8M
69
ARCTArcturus Therapeutics Holdings, Inc.$418.5M
66
DNAGinkgo Bioworks Holdings, Inc.$437.2M
40
EDITEditas Medicine, Inc.$414.3M
78
LRMRLarimar Therapeutics, Inc.$413.9M
30
KYTXKyverna Therapeutics, Inc.$438.8M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Atea Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVIR news & analysis

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 8 Sept 2026neutral

Atea Pharmaceuticals announced that CEO and Founder Jean-Pierre Sommadossi and other members of management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 12:20 p.m.

Why it matters — This gives AVIR watchers an opportunity to hear directly from company leadership about its late-stage oral antiviral programs at a major industry conference.

Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Atea Pharmaceuticals held its Q2 2026 earnings call, and the transcript of that call was published on Seeking Alpha. The item is limited to the availability of the earnings call transcript.

Why it matters — AVIR watchers would care because the earnings call transcript provides direct insight into the company's second-quarter 2026 financial results and management commentary.

Atea Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026positive

Atea Pharmaceuticals reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C, with the study meeting primary and secondary endpoints compared to the standard-of-care regimen sofosbuvir/velpatasvir.

Why it matters — The positive Phase III results bring Atea's lead hepatitis C candidate closer to potential regulatory submission, representing a significant milestone for the company's pipeline.

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 12 Aug 2026positive

Atea Pharmaceuticals announced its second quarter 2026 financial results and provided a business update. The company reported that its Phase 3 C-BEYOND trial of BEM/RZR met primary and secondary endpoints, including an 8-week treatment duration for HCV patients without cirrhosis.

Why it matters — The Phase 3 trial success with a short 8-week regimen could support a best-in-class profile for Atea's HCV treatment candidate BEM/RZR, a key pipeline catalyst for the company.

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

GlobeNewsWire · 5 Aug 2026neutral

Atea Pharmaceuticals announced it will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2026, and to provide a business update.

Why it matters — This item tells Atea investors when the company will report its second-quarter 2026 results and share a business update.

FAQ

Frequently asked questions about AVIR stock

What is the AVIR stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Atea Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVIR stock a buy right now?

Of the 3 analysts covering Atea Pharmaceuticals, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atea Pharmaceuticals, Inc. 67 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVIR?

As at 12 Sept 2026, Atea Pharmaceuticals, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).

Will AVIR stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +88.0% from the last close, and Ticker Nerd's factor model ranks Atea Pharmaceuticals, Inc. 67 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVIR stock forecast for 2030?

No analyst covering Atea Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $11 over the next 12 months.

How has AVIR stock performed over the past year?

Atea Pharmaceuticals, Inc. returned +69.4% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Atea Pharmaceuticals, Inc. do?

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections.

What is the latest news on AVIR?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference". Atea Pharmaceuticals announced that CEO and Founder Jean-Pierre Sommadossi and other members of management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 12:20 p.m.

Company

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections. Atea Pharmaceuticals’ current programs center on treatments for hepatitis C, including a late-stage regimen combining bemnifosbuvir and ruzasvir, as well as broader antiviral research across other RNA virus targets. The company also works on therapies for hepatitis E and other viral diseases, reflecting its emphasis on unmet medical needs in infectious disease. Its portfolio is designed around small-molecule oral medicines, which are intended to support convenient outpatient treatment options and address diseases that can require long-term or difficult-to-administer care. Based in Boston, Massachusetts, Atea Pharmaceuticals operates in the biopharmaceutical sector, where antiviral drug development plays a significant role in advancing treatment choices for patients and healthcare providers.

CEO Dr. Jean-Pierre Sommadossi Ph.D. · 55 employees · United States · https://ateapharma.com